Direct cytosolic siRNA delivery by reconstituted high density lipoprotein for target-specific therapy of tumor angiogenesis

Biomaterials

Volumn 35, Issue 25, 2014, Pages 7214-7227

  Ding, Yang ^a   Wang, Yazhe ^a   Zhou, Jianping ^a   Gu, Xiaochen ^b   Wang, Wei ^a   Liu, Congyan ^a   Bao, Xiuli ^a   Wang, Cheng ^a   Li, Yuanru ^a   Zhang, Qiang ^c  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b UNIVERSITY OF MANITOBA   (Canada)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Anti angiogenic therapy; Cholesterol conjugated siRNA; Direct cytosolic delivery; Reconstituted high density lipoprotein; Tumor selective accumulation; Vascular endothelial growth factor

Indexed keywords

CHOLESTEROL; CYTOLOGY; DISEASES; ENDOTHELIAL CELLS; ENZYME INHIBITION; FLUORESCENCE; INFRARED DEVICES; LIPOPROTEINS; NANOPARTICLES; RNA; TUMORS;

ANTI-ANGIOGENIC THERAPY; CHOLESTEROL-CONJUGATED SIRNA; CYTOSOLIC; HIGH DENSITY LIPOPROTEIN; TUMOR-SELECTIVE ACCUMULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR;

GENE THERAPY;

APOLIPOPROTEIN A1; CHOLESTEROL; DYE; HIGH DENSITY LIPOPROTEIN; LIPOFECTAMINE; LIPOPLEX; MESSENGER RNA; NANOPARTICLE; NUCLEASE; RECOMBINANT PROTEIN; SCAVENGER RECEPTOR BI; SMALL INTERFERING RNA; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

ALLERGIC REACTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER TISSUE; CELL MEMBRANE; CELLULAR DISTRIBUTION; CIRCULATION TIME; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; DRUG CONJUGATION; DRUG EFFICACY; ENDOSOME; EXPERIMENTAL RABBIT; FEMALE; FLUORESCENCE; FLUORESCENCE ACTIVATED CELL SORTING; GENE TARGETING; GENE TRANSFER; HARTLEY GUINEA PIG; HEMOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYSOSOME; MICROVASCULATURE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA DEGRADATION; RNA INTERFERENCE; TUMOR VASCULARIZATION; ANIMAL; CHEMISTRY; CYTOSOL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG SCREENING; GENETICS; GUINEA PIG; HEPG2 CELL LINE; MALE; MCF 7 CELL LINE; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PROCEDURES;

ANGIOGENESIS INHIBITORS; ANIMALS; APOLIPOPROTEIN A-I; CHOLESTEROL; CYTOSOL; DOWN-REGULATION; DRUG DELIVERY SYSTEMS; FEMALE; GUINEA PIGS; HEP G2 CELLS; HUMANS; MALE; MCF-7 CELLS; MICE; MICE, NUDE; NANOPARTICLES; NEOVASCULARIZATION, PATHOLOGIC; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902087150     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.05.009     Document Type: Article

References (46)

1. ®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma 2011, 52:1222-1229.
2. Matsumura Y., Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci 2009, 100:572-579.
3. Ng K.K., Lovell J.F., Zheng G. Lipoprotein-inspired nanoparticles for cancer theranostics. Acc Chem Res 2011, 44:1105-1113.
4. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
5. Abeylath S.C., Ganta S., Iyer A.K., Amiji M. Combinatorial-designed multifunctional polymeric nanosystems for tumor-targeted therapeutic delivery. Acc Chem Res 2011, 44:1009-1017.
6. Damiano M.G., Mutharasan R.K., Tripathy S., McMahon K.M., Thaxton C.S. Templated high density lipoprotein nanoparticles as potential therapies and for molecular delivery. Adv Drug Deliv Rev 2013, 65:649-662.
7. Rodrigueza W.V., Thuahnai S.T., Temel R.E., Lund-Katz S., Phillips M.C., Williams D.L. Mechanism of scavenger receptor class B type I-mediated selective uptake of cholesteryl esters from high density lipoprotein to adrenal cells. JBiol Chem 1999, 274:20344-20350.
8. Lacko A.G., Nair M., Paranjape S., Johnso S., McConathy W.J. High density lipoprotein complexes as delivery vehicles for anticancer drugs. Anticancer Res 2002, 22:2045-2049.
9. McMahon K.M., Mutharasan R.K., Tripathy S., Veliceasa D., Bobeica M., Shumaker D.K., et al. Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery. Nano Lett 2011, 11:1208-1214.
10. Ryther R.C., Flynt A.S., Phillips J.A., Patton J.G. siRNA therapeutics: big potential from small RNAs. Gene Ther 2005, 12:5-11.
11. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
12. Resnier P., Montier T., Mathieu V., Benoit J.P., Passirani C. Areview of the current status of siRNA nanomedicines in the treatment of cancer. Biomaterials 2013, 34:6429-6443.
13. Ge Y.L., Zhang X., Zhang J.Y., Hou L., Tian R.H. The mechanisms on apoptosis by inhibiting VEGF expression in human breast cancer cells. Int Immunopharmacol 2009, 9:389-395.
14. Kim S.H., Jeong J.H., Lee S.H., Kim S.W., Park T.G. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. JControl Release 2008, 129:107-116.
15. Morrissey D.V., Lockridge J.A., Shaw L., Blanchard K., Jensen K., Breen W., et al. Potent and persistent invivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005, 23:1002-1007.
16. Lee J.H., Lee K., Moon S.H., Lee Y., Park T.G., Cheon J. All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. Angew Chem Int Ed Engl 2009, 48:4174-4179.
17. Shahzad M.M., Mangala L.S., Han H.D., Lu C., Bottsford-Miller J., Nishimura M., et al. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 2011, 13:309-319.
18. Rui M., Tang H., Li Y., Wei X., Xu Y. Recombinant high density lipoprotein nanoparticles for target-specific delivery of siRNA. Pharm Res 2013, 30:1203-1214.
19. Ding Y., Wang W., Feng M., Wang Y., Zhou J., Ding X., et al. Abiomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy. Biomaterials 2012, 33:8893-8905.
20. Lerch P.G., Fortsch V., Hodler G., Bolli R. Production and characterization of a reconstituted high density lipoprotein for therapeutic applications. Vox Sang 1996, 71:155-164.
21. Liu T., Wu L.Y., Hopkins M.R., Choi J.K., Berkman C.E. Atargeted low molecular weight near-infrared fluorescent probe for prostate cancer. Bioorg Med Chem Lett 2010, 20:7124-7126.
22. Chen H., Gao J., Lu Y., Kou G., Zhang H., Fan L., et al. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy. JControl Release 2008, 128:209-216.
23. Wang F.Q., Barfield E., Dutta S., Pua T., Fishman D.A. VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion. Gynecol Oncol 2009, 115:414-423.
24. Murata N., Takashima Y., Toyoshima K., Yamamoto M., Okada H. Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice. JControl Release 2008, 126:246-254.
25. Chu T., Zhang Q., Li H., Ma W.C., Zhang N., Jin H., et al. Development of intravenous lipid emulsion of tanshinone IIA and evaluation of its anti-hepatoma activity invitro. Int J Pharm 2012, 424:76-88.
26. Frias J.C., Williams K.J., Fisher E.A., Fayad Z.A. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. JAm Chem Soc 2004, 126:16316-16317.
27. Lacko A.G., Nair M., Prokai L., McConathy W.J. Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs. Expert Opin Drug Deliv 2007, 4:665-675.
28. Vickers K.C., Palmisano B.T., Shoucri B.M., Shamburek R.D., Remaley A.T. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011, 13:423-433.
29. Kirschner M.B., Kao S.C., Edelman J.J., Armstrong N.J., Vallely M.P., van Zandwijk N., et al. Haemolysis during sample preparation alters microRNA content of plasma. PLoS One 2011, 6. e24145.
30. Mooberry L.K., Nair M., Paranjape S., McConathy W.J., Lacko A.G. Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. JDrug Target 2010, 18:53-58.
31. Soutschek J., Akinc A., Bramlage B., Charisse K., Constien R., Donoghue M., et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432:173-178.
32. Bricarello D.A., Smilowitz J.T., Zivkovic A.M., German J.B., Parikh A.N. Reconstituted lipoprotein: a versatile class of biologically-inspired nanostructures. ACS Nano 2011, 5:42-57.
33. Su Z., Niu J., Xiao Y., Ping Q., Sun M., Huang A., et al. Effect of octreotide-polyethylene glycol(100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine. Mol Pharm 2011, 8:1641-1651.
34. Zhang Z., Cao W., Jin H., Lovell J.F., Yang M., Ding L., et al. Biomimetic nanocarrier for direct cytosolic drug delivery. Angew Chem Int Ed Engl 2009, 48:9171-9175.
35. Alexis F., Pridgen E., Molnar L.K., Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008, 5:505-515.
36. Paillard A., Hindre F., Vignes-Colombeix C., Benoit J.P., Garcion E. The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability. Biomaterials 2010, 31:7542-7554.
37. Song J.J., Smith S.K., Hannon G.J., Joshua-Tor L. Crystal structure of Argonaute and its implications for RISC slicer activity. Science 2004, 305:1434-1437.
38. Acton S., Rigotti A., Landschulz K.T., Xu S., Hobbs H.H., Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996, 271:518-520.
39. Temel R.E., Walzem R.L., Banka C.L., Williams D.L. Apolipoprotein A-I is necessary for the invivo formation of high density lipoprotein competent for scavenger receptor BI-mediated cholesteryl ester-selective uptake. JBiol Chem 2002, 277:26565-26572.
40. Christie R.J., Matsumoto Y., Miyata K., Nomoto T., Fukushima S., Osada K., et al. Targeted polymeric micelles for siRNA treatment of experimental cancer by intravenous injection. ACS Nano 2012, 6:5174-5189.
41. Li X., Chen Y., Wang M., Ma Y., Xia W., Gu H. Amesoporous silica nanoparticle-PEI-fusogenic peptide system for siRNA delivery in cancer therapy. Biomaterials 2013, 34:1391-1401.
42. Al-Abd A.M., Lee S.H., Kim S.H., Cha J.H., Park T.G., Lee S.J., et al. Penetration and efficacy of VEGF siRNA using polyelectrolyte complex micelles in a human solid tumor model in-vitro. JControl Release 2009, 137:130-135.
43. Kim S.I., Shin D., Choi T.H., Lee J.C., Cheon G.J., Kim K.Y., et al. Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I. Mol Ther 2007, 15:1145-1152.
44. Nahleh Z.A. Molecularly targeted therapy in breast cancer: the new generation. Recent Pat Anticancer Drug Discov 2008, 3:100-104.
45. Kou R., SenBanerjee S., Jain M.K., Michel T. Differential regulation of vascular endothelial growth factor receptors (VEGFR) revealed by RNA interference: interactions of VEGFR-1 and VEGFR-2 in endothelial cell signaling. Biochemistry 2005, 44:15064-15073.
46. Li J., Nie S., Yang X., Wang C., Cui S., Pan W. Optimization of tocol emulsions for the intravenous delivery of clarithromycin. Int J Pharm 2008, 356:282-290.